New Approach against Chondrosoma Cells-Cold Plasma Treatment Inhibits Cell Motility and Metabolism, and Leads to Apoptosis.
CAL 78
SW 1353
TUNEL assay
caspase-3/7 assay
cold atmospheric pressure plasma
live/dead cell imaging
radius cell migration assay
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
17 Mar 2022
17 Mar 2022
Historique:
received:
14
02
2022
revised:
07
03
2022
accepted:
15
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
(1) Background: Chondrosarcoma (CS) is a malignant primary bone tumor with a cartilaginous origin. Its slow cell division and severely restricted vascularization are responsible for its poor responsiveness to chemotherapy and radiotherapy. The decisive factor for the prognosis of CS patients is the only adequate therapy-surgical resection. Cold atmospheric pressure plasma (CAP) is emerging as a new option in anti-cancer therapy. Its effect on chondrosarcomas has been poorly investigated. (2) Methods: Two CS cell lines-SW 1353 and CAL 78-were used. Various assays, such as cell growth kinetics, glucose uptake, and metabolic activity assay, along with two different apoptosis assays were performed after CAP treatment. A radius cell migration assay was used to examine cell motility. (3) Results: Both cell lines showed different growth behavior, which was taken into account when using the assays. After CAP treatment, a reduction in metabolic activity was observed in both cell lines. The immediate effect of CAP showed a reduction in cell numbers and in influence on this cell line's growth rate. The measurement of the glucose concentration in the cell culture medium showed an increase after CAP treatment. Live-dead cell imaging shows an increase in the proportion of dead cells over the incubation time for both cell lines. There was a significant increase in apoptotic signals after 48 h and 72 h for both cell lines in both assays. The migration assay showed that CAP treatment inhibited the motility of chondrosarcoma cells. The effects in all experiments were related to the duration of CAP exposure. (4) Conclusions: The CAP treatment of CS cells inhibits their growth, motility, and metabolism by initiating apoptotic processes.
Identifiants
pubmed: 35327489
pii: biomedicines10030688
doi: 10.3390/biomedicines10030688
pmc: PMC8945812
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Federal Ministry of Education and Research
ID : 03Z22DN11
Références
Oncologist. 2008 Mar;13(3):320-9
pubmed: 18378543
J Orthop Res. 1999 Nov;17(6):935-40
pubmed: 10632461
Int J Mol Sci. 2021 Nov 12;22(22):
pubmed: 34830132
Sci Rep. 2019 Apr 4;9(1):5627
pubmed: 30948733
Sci Rep. 2019 Oct 2;9(1):14210
pubmed: 31578342
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Free Radic Biol Med. 2019 Apr;134:374-384
pubmed: 30685405
Sci Rep. 2015 Dec 17;5:18339
pubmed: 26677750
Redox Biol. 2021 Oct;46:102116
pubmed: 34474394
Anticancer Res. 2016 Nov;36(11):5915-5922
pubmed: 27793916
Anticancer Res. 2020 Feb;40(2):841-846
pubmed: 32014927
Curr Opin Oncol. 2007 Jul;19(4):371-6
pubmed: 17545802
Theranostics. 2019 Jan 30;9(4):1066-1084
pubmed: 30867816
J Bone Joint Surg Br. 2002 Jan;84(1):93-9
pubmed: 11837841
Anticancer Res. 2017 Dec;37(12):6739-6744
pubmed: 29187451
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585948
Biochem Biophys Res Commun. 2016 May 13;473(4):1125-1132
pubmed: 27067049
Redox Biol. 2020 Feb;30:101423
pubmed: 31931281
Chem Sci. 2016 Jan 1;7(1):489-498
pubmed: 28791102
Clin Orthop Relat Res. 2007 Oct;463:166-72
pubmed: 17632422
BMC Cancer. 2012 Oct 15;12:473
pubmed: 23066891
Oxid Med Cell Longev. 2019 Sep 19;2019:8535163
pubmed: 31641425
Int J Mol Sci. 2020 Mar 26;21(7):
pubmed: 32225067
Free Radic Biol Med. 2021 May 1;167:12-28
pubmed: 33711420
Anticancer Res. 2020 Jul;40(7):3743-3749
pubmed: 32620613
Int J Mol Sci. 2021 Apr 08;22(8):
pubmed: 33917790
Expert Rev Mol Diagn. 2002 Sep;2(5):461-72
pubmed: 12271817
Sci Rep. 2016 Jul 07;6:29048
pubmed: 27383714
Oxid Med Cell Longev. 2017;2017:4396467
pubmed: 28761621
N Engl J Med. 2009 Oct 15;361(16):1570-83
pubmed: 19828534
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979114
Anticancer Res. 2018 Oct;38(10):5655-5663
pubmed: 30275184
Oxid Med Cell Longev. 2021 Dec 13;2021:2060986
pubmed: 34938381
Oncol Lett. 2020 Jan;19(1):283-290
pubmed: 31897140
Cancers (Basel). 2021 Apr 08;13(8):
pubmed: 33917880
Hematol Oncol Clin North Am. 2013 Oct;27(5):1021-48
pubmed: 24093174
Sci Rep. 2016 Jul 01;6:29098
pubmed: 27364563
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
Adv Anat Pathol. 2021 May 1;28(3):119-138
pubmed: 33480599
CA Cancer J Clin. 2006 Nov-Dec;56(6):366-75
pubmed: 17135693
J Clin Med. 2021 Feb 23;10(4):
pubmed: 33672274
F1000Res. 2018 Nov 20;7:
pubmed: 30519452
Int J Mol Sci. 2020 Sep 26;21(19):
pubmed: 32993057
Sci Rep. 2019 Mar 19;9(1):4866
pubmed: 30890760
Biol Chem. 2018 Dec 19;400(1):19-38
pubmed: 30403650
Sci Rep. 2012;2:636
pubmed: 22957140
ACS Appl Mater Interfaces. 2020 Aug 5;12(31):34548-34563
pubmed: 32648738